|Day Low/High||81.15 / 82.82|
|52 Wk Low/High||62.01 / 87.07|
Here are my five rules for handling earnings season.
Let's see if either of these names provide an entry this week.
Here's an updated strategy.
I am neutral on this market, and only a cool off of the hottest stocks can justify a further advance.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
The names include a veterinary drug concern plus companies with successful drugs on the market.
Investors and traders should approach MRK from the long side.
I am no longer as eager to sell these shares as when I discussed this merger pre-opening.
'It is not a healthy market when the generals are still going up and the troops are in retreat.'
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Especially when healthcare CEOs discus political issues with analysts and reporters.
Why are big institutions running and can you outrace them?
Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.
The real takeaway for AMZN for me, and the main reason that I am even in the name on a semi-permanent basis, is AWS.
How do the charts and indicators look ahead of their quarterly release?
One of pharma's biggest CEO's talks M&A action on the exchange.
And it is happening not a moment too soon.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
People will still take their medicine regardless of the state of the economy.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.